Fig. 2From: The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysisThis figure summarizes the quality assessment of the three included studiesBack to article page